Classification, diagnosis and treatment status of pulmonary hypertension from 2012 to 2019: a single center study in Yunnan province.
10.3760/cma.j.cn112148-20230919-00173
- Author:
Xiao Lan FENG
1
;
Yi Bing LU
1
;
Dong YANG
1
;
Qiang XUE
1
;
Ji Lei ZHANG
1
;
Chun Rong LIN
1
;
Pin GAN
1
;
Wei Hua ZHANG
1
;
Xue Feng GUANG
1
;
Hai Long DAI
1
Author Information
1. Department of Cardiology, Yan'an Affiliated Hospital, Kunming Medical University, Clinical Medicine Center and Key Laboratory for Cardiovascular Disease of Yunnan Province, Kunming 650051, China.
- Publication Type:Journal Article
- MeSH:
Child;
Aged;
Adolescent;
Middle Aged;
Humans;
Female;
Hypertension, Pulmonary/therapy*;
Retrospective Studies;
China/epidemiology*;
Familial Primary Pulmonary Hypertension;
Pulmonary Arterial Hypertension/complications*;
Heart Defects, Congenital
- From:
Chinese Journal of Cardiology
2023;51(11):1188-1193
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the classification, diagnosis and treatment status of patients with pulmonary hypertension (PH) in Yunnan province. Methods: This was a retrospective study. Hospitalized patients with PH at Yan'an Affiliated Hospital of Kunming Medical University from January 2012 to December 2019 were enrolled. The clinical data of enrolled patients, including demographic data, comorbidities, targeted drug therapy, echocardiography and right heart catheterization results, were obtained through the electronic medical record system. The composition ratio of PH, diagnosis and treatment were analyzed. Results: A total of 13 590 patients with PH were enrolled, accounting for 3.09% (13 590/440 056) of the total number of hospitalizations during the same period. The composition of PH was predominantly pulmonary arterial hypertension (PAH) (55.50% (7 542/13 590)), followed by pulmonary hypertension (PH) caused by left heart disease (24.16% (3 284/13 590)). Among them, PAH could be subdivided into four types: idiopathic pulmonary arterial hypertension (IPAH), PAH associated with connective tissue disease, PAH associated with portal hypertension, and PAH associated with congenital heart disease (CHD-PAH), with CHD-PAH as the predominating type (98.09% (7 398/7 542). Patients with PAH were predominantly adolescents. In hospitalized patients with PH, from 2012 to 2019, the proportion of children and adolescents showed a decreasing trend from year to year, and the proportion of middle-aged and older adults showed a significant increasing trend, and the proportion of female patients showed a gradual decreasing trend, and the proportion of patients with comorbid hypertension, diabetes mellitus, coronary artery disease, arrhythmia, and pneumonia showed an increasing trend. A total of 1 034 patients (7.61% (1 034/13 590)) underwent right heart catheterization. The concordance rate between echocardiographic and right heart catheterization findings was (86.98% (875/1 006)). A total of 2 574 (18.94%) of PH patients were treated with PAH targeted drugs, of which 58.16% (1 497/2 574) were treated with monotherapy. Among the PH patients treated with PAH targeted drugs, the majority of patients were PAH patients (86.44% (2 225/2 574)), and 83.53% (2 150/2 574) patients treated with PAH targeted drugs were CHD-PAH. Conclusions: Hospitalized PH patients in our center between 2012 and 2019 are predominantly CHD-PAH, and the proportion of patients receiving right heart catheterization and targeted drug therapy is relatively low. The percentage of middle-aged and elderly PH patients shows an increasing trend from year to year, as well as the percentage of those with concomitant comorbidities.
